Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Abroad (travel likely)RecruitingPHASE2

Conditions

Colorectal Cancer Metastatic · Liver Metastases · Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
Contact: Study coordinator (Casey Owens) · cdo4001@med.cornell.edu · 646-962-6046
Contact: Study coordinator (Myriam Elizaire-Williams) · mye4001@med.cornell.edu

Study leads

Manish Shah, M.D.
Principal Investigator
Weill Medical College of Cornell University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Colorectal Cancer · Liver Metastases

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research

Colorectal Cancer · Liver Metastases · Genetic Change

Abroad (travel likely)Recruiting

Barcelona, Spain

Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis

Colorectal Cancer · Liver Metastases · Liver Cancer

Abroad (travel likely)Recruiting

Cleveland, United States

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Colorectal Cancer · KRAS G12C Mutant Advanced Solid Tumors · Fulzerasib

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China